General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Methanobrevibacter smithii is a Gram-positive, non-spore-forming, strictly anaerobic, non-motile, oval-shaped bacterium. It has been detected in at least 17 gut microbiome compilation studies or metastudies. The DNA G+C content is 30.6%. Methanobrevibacter smithii is a common gut coloniser. (Balch1979)



  • This organism has been recovered from human faeces (gut) and sludge. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.

  • GENERAL CHARACTERISTICS (Balch1979);
    Character Response
  • pH
  • Acidity tolerance:
  • Grows optimally at pH 6.9-7.4.
  • 🌡
  • Temperature tolerance:
  • Grows optimally at 37-39℃.
  • Substrates assimilated or utilised:
  • acetate; formate;

  • N/A

  • Archaea are environmental organisms that are associated with the mucosa in mammals. In humans, Archaea are associated with the vaginal, oral, and intestinal mucosa. Because of the fastidious nature of these strict anaerobes, most current knowledge about the archaeal flora of mammals is derived from DNA-based analyses. In the human gut, methanogenic Archaea metabolize major fermentation products, such as alcohols, short chain organic acids, carbon dioxide (CO2), and hydrogen (H2). Until recently, the diversity of gut methanogens was thought to be limited to two species: Methanobrevibacter smithii, the most abundant methanogenic Archaea found in the human gut, and Methanosphaera stadtmanae, which is seldom detected in the human gut. In the gut, M. smithii converts H2, CO2, and formate into CH4 using carbon as the terminal electron acceptor; this redox reaction sustains anaerobic respiration, which allows for the production of ATP. This archaeon can also remove fermentation end products, such as methanol and ethanol, produced by other bacteria lacking a methanogenic pathway. [PMID: 19759898]

    Methanobrevibacter smithii may impact human health, but its beneficial effect is still questionable. [PMID: 29449383] In the gut, M. smithii converts H2, CO2, and formate into CH4 using carbon as the terminal electron acceptor; this redox reaction sustains anaerobic respiration, which allows for the production of ATP. Until recently, the diversity of gut methanogens was thought to be limited to two species: Methanobrevibacter smithii, the most abundant methanogenic Archaea found in the human gut, and Methanosphaera stadtmanae, which is seldom detected in the human gut. This archaeon can also remove fermentation end products, such as methanol and ethanol, produced by other bacteria lacking a methanogenic pathway. [PMID: 19759898]

  • GutFeeling KnowledgeBase COMMENTS [Website]

    Methanobrevibacter smithii (strain ATCC 35061 / DSM 861) is a methanogenic Euryarchaeote which is the dominant archeon in the human gut ecosystem and makes up 10% of all anaerobes in the colons of healthy adults. Studies in gnotobiotic mice indicate that M. smithii affects the specificity and efficiency of bacterial digestion of dietary polysaccharide, thereby influencing host calorie harvest and adiposity. Comparison of the gut microbial communities of genetically obese and lean mice has shown that the former contain an enhanced representation of genes involved in polysaccharide degradation, possess more archaea and exhibit a greater capacity to promote adiposity when transplanted in germ-free recipients. These findings suggest that M. smithii may be a therapeutic target for reducing energy harvest in obese humans. [UP000001992]

    Methanobrevibacter is a fastidious archaeal microorganism and obligate anaerobe. It can be cultivated in a pressurized anaerobic atmosphere of 80% hydrogen and 20% carbon dioxide. Among Methanobrevibacter species, M. smithii is a near-ubiquitous resident of the human intestinal microbiome. The prevalence of methanogens in humans has been reported to be dependent on the age of the human host; populations increase gradually throughout childhood, reaching a maximum abundance level in adults. A methanogenic strain, KB11, was purified from the feces of a healthy 43-year-old Korean male. This is the first human gut methanogen isolated from South Korea. [PMID: 29449383]


  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Euryarchaeota Class:  Methanobacteria Order:  Methanobacteriales Family:  Methanobacteriaceae Genus:  Methanobrevibacter Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Oval-shaped
    Health:  Unknown
    Source:  human faeces (gut) and sludge
    DNA G+C(%):  30.6
    Opt. T:  37-39℃
    Opt. pH:  6.9-7.4

    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Acetate:  + Formate:  +

    References


    SPECIFIC REFERENCES FOR METHANOBREVIBACTER SMITHII
  • Balch1979 - Methanogens: reevaluation of a unique biological group.
  • Gao2020 - Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis
  • Bhute2017 - Gut Microbial Diversity Assessment of Indian Type-2-Diabetics Reveals Alterations in Eubacteria, Archaea, and Eukaryotes
  • Borgo2017 - Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Ghavami2018 - Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases
  • Ignacio2016 - Correlation between body mass index and faecal microbiota from children
  • Jhangi2014 - Increased Archaea Species and Changes with Therapy in Gut Microbiome of Multiple Sclerosis Subjects
  • Li2019c - Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China
  • Unger2016 - Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR METHANOBREVIBACTER SMITHII
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Karlsson2013 - Gut metagenome in European women with normal, impaired and diabetic glucose control
  • King2019 - Baseline human gut microbiota profile in healthy people and standard reporting template.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • LeChatelier2013 - Richness of human gut microbiome correlates with metabolic markers
  • Minerbi2019 - Altered microbiome composition in individuals with fibromyalgia
  • Nam2008a - Bacterial, archaeal, and eukaryal diversity in the intestines of Korean people.
  • Nielsen2014 - MetaHIT Consortium. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes.
  • Rothschild2018 - Environment dominates over host genetics in shaping human gut microbiota.
  • Tyakht2013 - Human gut microbiota community structures in urban and rural populations in Russia.
  • Urban2020 - Altered Fecal Microbiome Years after Traumatic Brain Injury
  • Wang2018 - A metagenome-wide association study of gut microbiota in asthma in UK adults
  • Wang2018a - Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................